Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Express Scripts
Boehringer Ingelheim
McKesson
Medtronic

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR ODOMZO


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Odomzo

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02086552 ↗ Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Active, not recruiting National Cancer Institute (NCI) Phase 2 2014-01-17 This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
NCT02086552 ↗ Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Active, not recruiting Novartis Pharmaceuticals Phase 2 2014-01-17 This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
NCT02086552 ↗ Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma Active, not recruiting Mayo Clinic Phase 2 2014-01-17 This phase II trial studies how well sonidegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Sonidegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay multiple myeloma from coming back after a stem cell transplant.
NCT02129101 ↗ Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Completed National Cancer Institute (NCI) Phase 1 2014-05-01 This phase I/Ib trial studies the side effects and best dose of azacitidine and sonidegib or decitabine and so see how well they work in treating patients with myeloid malignancies. The hedgehog (Hh) signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hh-ligand cell surface receptor Smo. Sonidegib binds to the Hh cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and the inhibition of cancer cells. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with sonidegib or decitabine may be a safe and successful treatment for patients with myeloid malignancies.
NCT02129101 ↗ Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies Completed Mayo Clinic Phase 1 2014-05-01 This phase I/Ib trial studies the side effects and best dose of azacitidine and sonidegib or decitabine and so see how well they work in treating patients with myeloid malignancies. The hedgehog (Hh) signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hh-ligand cell surface receptor Smo. Sonidegib binds to the Hh cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and the inhibition of cancer cells. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine together with sonidegib or decitabine may be a safe and successful treatment for patients with myeloid malignancies.
NCT02303041 ↗ Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Terminated National Cancer Institute (NCI) Phase 2 2015-02-01 This pilot trial studies how well sonidegib and buparlisib work in treating patients with basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Odomzo

Condition Name

Condition Name for Odomzo
Intervention Trials
Nevoid Basal Cell Carcinoma Syndrome 1
Stage III Pancreatic Cancer AJCC v8 1
Basal Cell Carcinoma of Skin, Site Unspecified 1
Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Odomzo
Intervention Trials
Carcinoma 4
Skin Neoplasms 3
Carcinoma, Basal Cell 3
Leukemia, Myelomonocytic, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Odomzo

Trials by Country

Trials by Country for Odomzo
Location Trials
United States 6
Italy 1
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Odomzo
Location Trials
Minnesota 3
Florida 1
Arizona 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Odomzo

Clinical Trial Phase

Clinical Trial Phase for Odomzo
Clinical Trial Phase Trials
Phase 2 4
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Odomzo
Clinical Trial Phase Trials
Recruiting 3
Completed 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Odomzo

Sponsor Name

Sponsor Name for Odomzo
Sponsor Trials
National Cancer Institute (NCI) 4
Mayo Clinic 3
Novartis Pharmaceuticals 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Odomzo
Sponsor Trials
Other 6
NIH 4
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Colorcon
McKinsey
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.